This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 4 weeks of treatment with TZP. These measures will also be compared to a group of adults without diabetes (who will not receive treatment with TZP) to assess how metabolism of energy and nutrients is different in T1D compared to people without diabetes.

Start Date01 Dec 2025

Sponsor / Collaborator

The Garvan Institute of Medical Research

NCT06651177

/ Not yet recruitingPhase 2IIT

NIDA CTN-0152: Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: a Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

Start Date16 Sep 2025

Sponsor / Collaborator

National Institute on Drug Abuse

NCT06801015

/ Not yet recruitingPhase 4IIT

A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

Start Date15 Aug 2025

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

1,101

Literatures (Medical) associated with Tirzepatide

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

Author: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

01 Dec 2025·Current heart failure reports

Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients

Review

Author: Patel, Ravi ; Ukah, Joan Dumebi ; Adejumo, Faith Adedayo ; Olatunji, Gbolahan ; Babalola, Adetola Emmanuel ; Ndakotsu, Andrew ; Kokori, Emmanuel ; Aderinto, Nicholas ; Abraham, Israel Charles

PURPOSE OF REVIEW:

Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent among individuals with obesity, primarily due to metabolic dysfunction and structural cardiac remodeling. This review explores the emerging therapeutic role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing HFpEF in obese populations.

RECENT FINDINGS:

Recent clinical trials, including the STEP-HFpEF and SUMMIT studies, have shown that GLP-1 RAs such as semaglutide and tirzepatide significantly reduce body weight (13.3% and 13.9%, respectively), enhance exercise capacity (increases of 21.5m and 26m in 6-minute walk distance), and improve quality of life (19.5 and 16.6-point increases in KCCQ-CSS scores). Additionally, both agents demonstrated marked reductions in systemic inflammation, with C-reactive protein levels decreasing by 38.8% and 43.5%, respectively. GLP-1 RAs represent a promising class of agents targeting the cardiometabolic axis in HFpEF, offering meaningful improvements in functional capacity and symptom burden among obese patients. However, current evidence is limited by short trial durations, lack of population diversity, and insufficient long-term data. Future research should focus on more inclusive cohorts and extended outcomes such as hospitalization rates and cardiovascular events to fully define the long-term safety and efficacy of GLP-1 RAs in HFpEF management.

01 Sep 2025·Obesity Pillars

Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea

Article

Author: Belarj, Soufiane ; Reyes, Anita ; Ziemke, Florencia ; Istfan, Nawfal ; Esguerra, Jem

Background:

Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disruption to treatment. Sea-Band® is a drug-free, class II FDA-cleared medical device for relief of nausea in motion sickness, morning sickness, chemotherapy and anesthesia induced nausea. The device is a set of soft, elastic, reusable acupressure wristbands (ACW) with a skin-facing plastic button worn below the wrist crease applying pressure at acupoint pericardium 6. We hypothesized that ACW was an effective tool for GLP-1a associated nausea.

Methods:

This was a one-arm, open-label, non-randomized, prospective interventional study evaluating the antiemetic effect of ACW in non-pregnant adults on GLP-1as with nausea. GLP-1a were semaglutide or tirzepatide. Exclusion criteria were patients on GLP-1a without nausea, recent use of antiemetic medications, other nausea-related conditions, history of gastroparesis, and uncontrolled gastroesophageal reflux disease. Patients were shown how to properly place and use ACW at the onset of nausea and were followed weekly for 4 weeks. Follow-ups assessed frequency of nausea, ACW use frequency and duration, and change in nausea.

Results:

359 episodes of nausea were recorded amongst 31 adult participants over 4 weeks. Adults, mean age 55, mean BMI 34, mean HbA1c 5.9 %, reported nausea over 80 % of the time on a weekly basis. ACW were used in all recorded episodes of nausea. Medication doses were kept stable throughout the duration of this study. Nausea relief was achieved within 5 min in one third of episodes, and in over 5 min but under 20 min in the remainder of the episodes. A logistic regression model was used to evaluate the likelihood of nausea relief. A consistent rate of nausea relief over 80 % was observed during the study period, adjusting for the correlation between reduced nausea episodes and reduced episodes.

Conclusion:

Although not a controlled trial, this pilot, proof of concept, pragmatic study suggests that ACW may offer a safe, self-administered, reusable, and drug-free option for managing GLP-1a associated nausea.ACW's nausea reducing effect was seen in over 80 % of episodes, and remained consistent throughout the study period. One third of participants experienced relief within 5 min of wearing ACW in the first three weeks. Given the relatively small sample size of the population, further large-scale investigations are justified. Nausea is common in day-to-day real-world use of GLP-1as, and our results suggest that using ACW may provide a first-line therapeutic intervention used ad libitum to tame a disruptive symptom, improve day-to-day well-being, and positively impact a person's treatment journey on GLP-1a.

1,316

News (Medical) associated with Tirzepatide

16 Jun 2025

·www.prnewswire.com

Peptide and Anti-Aging Specialist Dr. Daniel Benhuri Now Offering Advanced Peptide Therapy, Including Semaglutide, in Beverly Hills and Los Angeles

Dr. Daniel Benhuri, a board-certified concierge physician in Beverly Hills, has introduced personalized peptide therapy to help patients optimize energy, metabolism, immunity, and recovery. The new service is available in-office or via concierge care throughout Beverly Hills and Los Angeles. BEVERLY HILLS, Calif. , June 16, 2025 /PRNewswire/ -- Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now offering a full range of advanced peptide therapies designed to support weight loss, healing, hormone balance, sexual wellness, and cellular rejuvenation. Serving patients throughout Beverly Hills and the greater Los Angeles area, Dr. Benhuri's peptide programs now include widely requested options like Semaglutide, Tirzepatide, Tesamorelin, PT-141, BPC-157, and NAD+. Continue Reading Daniel Benhuri MD Peptides are short chains of amino acids that function as biological messengers, helping regulate metabolism, inflammation, recovery, and tissue repair. Dr. Benhuri's therapy protocols are fully customized based on labs, medical history, and patient goals—and are now available through in-office visits or concierge care across Los Angeles. "Peptide therapy is a powerful tool that allows us to treat the root causes of fatigue, weight gain, inflammation, and low libido," said Dr. Benhuri. "These are evidence-based, well-tolerated therapies that fit perfectly into our concierge wellness model. Our patients want to optimize their lives, and peptides help us deliver exactly that." Highlights of Dr. Benhuri's peptide therapy offerings include: Semaglutide and Tirzepatide (GLP-1 agonists): Support sustainable weight loss by regulating appetite and improving insulin sensitivity. Tesamorelin: Helps reduce visceral fat and promote lean muscle development. PT-141: Enhances sexual desire and performance in both men and women. BPC-157: Accelerates healing of soft tissue injuries and provides anti-inflammatory benefits. NAD+ Therapy: Though not a peptide, NAD+ is a key coenzyme used for energy metabolism, anti-aging, and cognitive enhancement. Dr. Benhuri's comprehensive programs begin with a detailed consultation and lab review. Based on individual needs, patients receive a personalized treatment plan that may include injectable peptides, nasal sprays, or topical solutions—all sourced from high-quality U.S. compounding pharmacies. Patients also benefit from ongoing clinical monitoring and adjustments as part of his concierge approach. Known for his expertise in preventive care, weight management, and regenerative medicine, Dr. Benhuri offers these new services as a natural extension of his commitment to helping patients feel better, function better, and age with confidence. More About Dr. Daniel Benhuri Dr. Daniel Benhuri is a highly respected internal medicine and primary care physician serving patients in Beverly Hills and the surrounding areas. He offers a vast array of services, including advanced diagnostic imaging, executive physicals, medical weight loss plans, preventive care, and aesthetic treatments. By integrating concierge care and cutting-edge technology, Dr. Benhuri delivers an unmatched level of patient-focused care. His practice is located at 9400 Brighton Way, Suite 210, Beverly Hills, CA 90210. For more information or to schedule an appointment, visit or call (310) 362-1255. Media Contact Dr. Daniel Benhuri (310) 362-1255 SOURCE Daniel Benhuri M.D. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

16 Jun 2025

·pipelinereview.com

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, IN, USA I June 16, 2025 I MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MBX 4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist prodrug for the treatment of obesity. “MBX 4291 is designed to be a potential best-in-class, once-monthly injectable for the treatment of obesity,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “We believe MBX 4291 could potentially offer less frequent dosing and improved gastrointestinal tolerability, which may result in better adherence and increased maximal weight loss. Following IND clearance, we plan to initiate a Phase 1 trial evaluating MBX 4291 in healthy overweight volunteers in the third quarter of 2025. We are also advancing multiple early-stage obesity candidates using our proprietary platform to build precision peptides with differentiating characteristics.” About MBX 4291 MBX 4291 is an investigational long-acting GLP-1/GIP receptor co-agonist prodrug in development as a potential treatment for obesity. It was designed using the Company’s novel, proprietary PEP™ platform as a long-acting dual agonist with the potential for once-monthly dosing, improved gastrointestinal tolerability, and increased maximal weight loss. In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, an approved weekly GLP-1/GIP co-agonist. In addition, extended duration of action of the active component of MBX 4291 was observed in additional preclinical studies compared to tirzepatide, supporting the potential for once-monthly administration. About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate canvuparatide (MBX 2109), in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); imapextide (MBX 1416), in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, with an IND currently under FDA review, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn. About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. SOURCE: MBX Biosciences

Phase 2Phase 1IND

16 Jun 2025

·www.einpresswire.com

GenBio Addresses Maintaining Glucose Homeostasis

Hormonal and neural regulatory mechanisms that maintain blood glucose levels within a very narrow range Science is fun. Science is curiosity. We all have natural curiosity. Science is a process of investigating. It's posing questions and coming up with a method. It's delving in.” — Sally Ride ALISO VIEJO, CA, UNITED STATES, June 16, 2025 / EINPresswire.com / -- Glucose from a diet is the major energy source for humans and other mammals. Blood glucose concentrations increase rapidly after food intake and then decline as glucose is used or stored. Since nutrient intake is irregular but energy requirement is continuous, the body needs to store glucose, usually as glycogen, mainly in the muscles and liver. Two peptides produced by the pancreas, insulin and glucagon, control glucose storage by enhancing glucose uptake and glycogen breakdown, respectively. Persistent high blood glucose concentrations result from diminished insulin production as in type 1 diabetes or insulin resistance, a decreased cellular response to insulin as in type 2 diabetes . Type 2 diabetes is a chronic disease defined by hyperglycemia leading to microvascular and macrovascular damage. The prevalence of diabetes has been increasing globally since 1990, attributed to living environments and lifestyle leading to poorer nutrition and increased sedentary behaviour. The International Diabetes Federation estimates that 11.1% of the world’s adult population aged 20-79 years, around 452 million people, is living with diabetes, with 4 in 10 of these people unaware that they have the disease. Diabetes is more prevalent in people aged 65 years and older, including 122 million of this population of 652 million, or around 19%; further, prediabetes affects 48% of the 26 million older adults in the USA. The risk to these patients is increased by multiple comorbidities, increased incidence of hypoglycemia, increased dependence on care and worsening frailty. Cardiovascular disease remains the leading cause of death in type 2 diabetics, even though a marked decrease in all-cause mortality of 30–35% in diabetics in the USA and England has been related to decreases in mortality from cardiovascular disease. Cancer rates have remained unchanged in diabetes patients, but this is now an increased percentage of deaths while mortality rates from dementia and liver disease have increased. Lifestyle modifications, including nutrition and exercise, are the foundation for the management of type 2 diabetes. Drug treatment of diabetes now includes metformin, which lowers liver production of glucose, sulphonylureas such as glyburide, which stimulate insulin production, thiazolidinediones such as pioglitazone which increase glucose uptake into tissues, prompting insulin secretion and decreasing appetite with glucagon-like peptide-1 receptor agonists, including semiglutide, combined glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists such as tirzepatide and preventing the reabsorption of glucose in the kidneys by sodium-glucose cotransporter-2 inhibitors such as dapagliflozin and empagliflozin. Research is continuing, so potential clinical use of adiponectin and fibroblast growth factor 21 could allow personalized approaches to lower blood glucose concentrations. Healthy eating plans are essential for long-term control of diabetes. Preclinical trials with anthocyanin-containing foods have shown regulation of blood glucose concentrations, improved gut microbiota, reduced insulin resistance and inflammation, and changed adipocyte function. Large prospective cohort trials in people in the USA have shown an inverse relationship between a healthy plant-based diet and the risk of developing diabetes. Dietary anthocyanin intake was linked to a 15% lower incidence of type 2 diabetes in 8 cohort studies involving 394,913 participants. In a summary of 18 human trials in type 2 diabetes from the last 5 years, anthocyanins reduced blood glucose and HbA1c concentrations and improved insulin secretion and resistance, especially in at-risk groups. Further, diets containing polyphenols such as anthocyanins may reduce the risk of developing diabetes. The incidence of type 2 diabetes decreased by 5% when the intake of anthocyanins increased by 7.5 mg/day. As examples, plums such as the Queen Garnet, Illawarra and Davidson’s varieties may contain 250-500 mg anthocyanins per 100g fruit. Other important dietary sources of anthocyanins include raspberries, bilberries, chokeberries, mulberries, and saskatoon berries. These clinical investigations support the preclinical studies that anthocyanins simultaneously affect many targets associated with type 2 diabetes. These studies reinforce that improving nutritional status in people with diabetes by adding anthocyanin-containing fruit to current treatment regimens is likely to improve clinical outcomes. Nutrition, exercise, and treatment with antidiabetic medications remain the key approaches to the treatment of type 2 diabetes. Todd D. Sonoga GenBio Inc. +1 949-705-8021 email us here Visit us on social media: LinkedIn Facebook X GenBio Inc Elevator Pitch Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Obesity Hypoventilation Syndrome	NDA/BLA	China	Eli Lilly & Co.	15 Sep 2024
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Croatia	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Czechia	Eli Lilly & Co.	01 Jun 2025
Colitis, Ulcerative	Phase 3	Denmark	Eli Lilly & Co.	01 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Neoplasms	-	Tirzepatide	nrgaunldgt(zvttnudfzr) = dzofkbfnfb qyoxrxoxjx (rrgvbkwxmg )	Positive	30 May 2025
				GLP-1 receptor agonists	nrgaunldgt(zvttnudfzr) = jsgcswoynt qyoxrxoxjx (rrgvbkwxmg )
NCT05822830 (SURMOUNT-5, Pubmed \| N Engl J Med) Manual	Phase 3	Obesity	751	TirzepatideTirzepatide 10 mg or 15 mg	mtqgyjenug(fposaasfwh) = gcoadjdsqb mgixvdoycv (dgekkkcuzr, -21.4 to -19.1) View more	Positive	11 May 2025
				Semaglutide Semaglutide 1.7 mg or 2.4 mg	mtqgyjenug(fposaasfwh) = kyptvpcblm mgixvdoycv (dgekkkcuzr, -14.9 to -12.6) View more
NCT05564039 (SURPASS-SWITCH, Pubmed \| Ann Intern Med)	Phase 4	-	282	Tirzepatide	jerlyerhit(xdlozwfozw) = dkmjlhfouk jvzxiasnnq (azbvpeinnx, 0.07) View more	Positive	01 May 2025
				Dulaglutide	jerlyerhit(xdlozwfozw) = oelpliwvqv jvzxiasnnq (azbvpeinnx, 0.08) View more
NCT05412004 (SURMOUNT-OSA, CTgov)	Phase 3	Sleep Apnea, Obstructive \| Obesity	469	Tirzepatide (Tirzepatide MTD_GPI1)	kyygjecsax(lqbtxalxcq) = psysdtcziy mfmjsudlug (msdlrfttpf, 2.06) View more	-	30 Apr 2025
				Placebo (Placebo_GPI1)	kyygjecsax(lqbtxalxcq) = eqrrniykes mfmjsudlug (msdlrfttpf, 2.11) View more
NCT05978713 (CTgov)	Phase 1	-	11	Tirzepatide	rtqvqhgnuv(wayoslvjqm) = hxltlcyoza qvtufnriqp (gpwjxzwcgx, NA) View more	-	27 Apr 2025
S30.005 (AAN2025)	Not Applicable	Diabetes Mellitus, Type 2	-	Tirzepatide	rgjvwpnjub(uodclwwabw): HR = 1.18 (95% CI, 1.07 - 1.29) View more	Positive	07 Apr 2025
				Semaglutide
NCT04847557 (Pubmed \| Circulation)	Phase 3	Heart Failure, Diastolic	731	Tirzepatide	nwcdeqvzre(fcamqgazes) = xkkdyhgbyz wkhjgdjzuk (atrfgyipcq )	Positive	11 Mar 2025
NCT03861052 (SURPASS J-mono, Pubmed \| Diabetes Ther)	Phase 3	Diabetes Mellitus, Type 2 C-peptide	636	Tirzepatide 5 mg	byvyuhugdj(pdnjnyvghl) = tfxeovemvm twthiixeui (gehfjgqqqa ) View more	Positive	14 Feb 2025
				Tirzepatide 10 mg	byvyuhugdj(pdnjnyvghl) = nnttjvzmqg twthiixeui (gehfjgqqqa ) View more
NCT04166773 (SYNERGY-NASH, CTgov)	Phase 2	Nonalcoholic Steatohepatitis	190	Tirzepatide (5 mg Tirzepatide)	kxvgacprry = koppdjotjt fzmleugjnz (onxkeugzsv, lguwnrejoj - nvueffnyrf) View more	-	24 Jan 2025
				Tirzepatide (10 mg Tirzepatide)	kxvgacprry = pjrnunacnj fzmleugjnz (onxkeugzsv, gllsrtemru - kvojvsshgm) View more
Pubmed Manual	Not Applicable	Overweight \| Obesity	15,491	Tirzepatide 15 mg once weekly	gjmpeottie(tvxbynosoj) = rmxkjrdzed fpmizchuio (qjeumtcgce )	Positive	07 Jan 2025
				Semaglutide 2.4 mg once weekly	gjmpeottie(tvxbynosoj) = fzforqzfhw fpmizchuio (qjeumtcgce )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis